表紙
市場調查報告書

神經肽Y受體2型:開發中產品分析

Neuropeptide Y Receptor Type 2 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 520773
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
神經肽Y受體2型:開發中產品分析 Neuropeptide Y Receptor Type 2 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 35 Pages
簡介

本報告提供以神經肽Y受體2型為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

神經肽Y受體2型;概要

神經肽Y受體2型;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Gila Therapeutics Inc
  • Novo Nordisk A/S
  • XL-protein GmbH

藥物簡介

暫停中的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2063TDB

Summary

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity and Epilepsy.

The latest report Neuropeptide Y Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
  • The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved in Therapeutics Development
  • CombiGene AB
  • Gila Therapeutics Inc
  • Novo Nordisk AS
  • Takeda Pharmaceutical Co Ltd
  • XL-protein GmbH
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles
  • CG-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GT-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NN-9747 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PYY-1119 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XL-310 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 18, 2019: CombiGene receives a second payment of EUR 1.21 million from Horizon 2020
  • Nov 06, 2019: CombiGene: Two significant steps towards the first human studies for CG01
  • Oct 14, 2019: CombiGene signs agreement with Cobra Biologics for production of candidate drug CG01
  • Sep 10, 2019: CombiGene chooses the CRO company Northern Biomedical Research as partner for upcoming preclinical biodistribution and safety studies
  • May 15, 2018: EU allocates EUR 3.6 million in funding for development of CombiGenes cutting-edge gene therapy technology
  • Feb 19, 2018: Final data from long-term study of CombiGene epilepsy treatment indicate clearly positive effects in the form of fewer and shorter seizures.
  • Dec 14, 2017: Study with brain tissue from human epilepsy patients confirms that brain cells express CombiGene's candidate drug CG01
  • Dec 06, 2017: Initial data from the long-term study on CombiGene's candidate drug for treating epilepsy indicate positive effects in the form of fewer seizures
  • Nov 09, 2012: Novel treatment strategies for epilepsy
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by CombiGene AB, H2 2019
  • Pipeline by Gila Therapeutics Inc, H2 2019
  • Pipeline by Novo Nordisk AS, H2 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Pipeline by XL-protein GmbH, H2 2019
  • Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top